Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
China
Anhui Provincial Hospital, Hefei, Anhui Peking University Cancer Hospital & Institute-Department of Gastrointestinal Oncology, Beijing, Beijing Municipality The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei